vs

Side-by-side financial comparison of Protagonist Therapeutics, Inc (PTGX) and Rapid7, Inc. (RPD). Click either name above to swap in a different company.

Rapid7, Inc. is the larger business by last-quarter revenue ($217.4M vs $170.6M, roughly 1.3× Protagonist Therapeutics, Inc). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs 1.4%, a 75.7% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs 0.5%). Protagonist Therapeutics, Inc produced more free cash flow last quarter ($182.8M vs $36.4M).

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.

Rapid7, Inc. is a leading global cybersecurity company that offers a full portfolio of solutions including vulnerability management, threat detection and response, cloud security, and security analytics. It serves enterprises, SMBs, and public sector entities across industries like tech, healthcare, finance, and manufacturing worldwide, helping clients address and mitigate cyber risks efficiently.

PTGX vs RPD — Head-to-Head

Bigger by revenue
RPD
RPD
1.3× larger
RPD
$217.4M
$170.6M
PTGX
Growing faster (revenue YoY)
PTGX
PTGX
+183.9% gap
PTGX
184.4%
0.5%
RPD
Higher net margin
PTGX
PTGX
75.7% more per $
PTGX
77.2%
1.4%
RPD
More free cash flow
PTGX
PTGX
$146.4M more FCF
PTGX
$182.8M
$36.4M
RPD

Income Statement — Q4 FY2024 vs Q4 FY2025

Metric
PTGX
PTGX
RPD
RPD
Revenue
$170.6M
$217.4M
Net Profit
$131.7M
$3.1M
Gross Margin
68.9%
Operating Margin
74.3%
1.0%
Net Margin
77.2%
1.4%
Revenue YoY
184.4%
0.5%
Net Profit YoY
381.7%
44.1%
EPS (diluted)
$2.01
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PTGX
PTGX
RPD
RPD
Q4 25
$217.4M
Q3 25
$218.0M
Q2 25
$214.2M
Q1 25
$210.3M
Q4 24
$170.6M
$216.3M
Q3 24
$214.7M
Q2 24
$208.0M
Q1 24
$255.0M
$205.1M
Net Profit
PTGX
PTGX
RPD
RPD
Q4 25
$3.1M
Q3 25
$9.8M
Q2 25
$8.3M
Q1 25
$2.1M
Q4 24
$131.7M
$2.2M
Q3 24
$15.4M
Q2 24
$6.5M
Q1 24
$207.3M
$1.4M
Gross Margin
PTGX
PTGX
RPD
RPD
Q4 25
68.9%
Q3 25
70.2%
Q2 25
70.6%
Q1 25
71.7%
Q4 24
69.5%
Q3 24
70.6%
Q2 24
70.7%
Q1 24
70.3%
Operating Margin
PTGX
PTGX
RPD
RPD
Q4 25
1.0%
Q3 25
2.7%
Q2 25
1.6%
Q1 25
-0.0%
Q4 24
74.3%
3.4%
Q3 24
6.0%
Q2 24
2.5%
Q1 24
80.9%
4.7%
Net Margin
PTGX
PTGX
RPD
RPD
Q4 25
1.4%
Q3 25
4.5%
Q2 25
3.9%
Q1 25
1.0%
Q4 24
77.2%
1.0%
Q3 24
7.2%
Q2 24
3.1%
Q1 24
81.3%
0.7%
EPS (diluted)
PTGX
PTGX
RPD
RPD
Q4 25
$0.05
Q3 25
$0.15
Q2 25
$0.13
Q1 25
$0.03
Q4 24
$2.01
$0.08
Q3 24
$0.21
Q2 24
$0.09
Q1 24
$3.26
$0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PTGX
PTGX
RPD
RPD
Cash + ST InvestmentsLiquidity on hand
$418.9M
$474.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$675.3M
$154.7M
Total Assets
$744.7M
$1.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PTGX
PTGX
RPD
RPD
Q4 25
$474.7M
Q3 25
$407.1M
Q2 25
$511.7M
Q1 25
$493.5M
Q4 24
$418.9M
$521.7M
Q3 24
$443.7M
Q2 24
$442.6M
Q1 24
$322.6M
$411.7M
Stockholders' Equity
PTGX
PTGX
RPD
RPD
Q4 25
$154.7M
Q3 25
$127.2M
Q2 25
$90.4M
Q1 25
$52.7M
Q4 24
$675.3M
$17.7M
Q3 24
$-5.1M
Q2 24
$-52.6M
Q1 24
$560.4M
$-86.4M
Total Assets
PTGX
PTGX
RPD
RPD
Q4 25
$1.7B
Q3 25
$1.7B
Q2 25
$1.6B
Q1 25
$1.6B
Q4 24
$744.7M
$1.7B
Q3 24
$1.6B
Q2 24
$1.5B
Q1 24
$629.3M
$1.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PTGX
PTGX
RPD
RPD
Operating Cash FlowLast quarter
$184.2M
$37.6M
Free Cash FlowOCF − Capex
$182.8M
$36.4M
FCF MarginFCF / Revenue
107.1%
16.8%
Capex IntensityCapex / Revenue
0.8%
0.5%
Cash ConversionOCF / Net Profit
1.40×
12.01×
TTM Free Cash FlowTrailing 4 quarters
$101.7M
$146.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PTGX
PTGX
RPD
RPD
Q4 25
$37.6M
Q3 25
$39.0M
Q2 25
$47.5M
Q1 25
$29.8M
Q4 24
$184.2M
$63.8M
Q3 24
$44.0M
Q2 24
$32.9M
Q1 24
$-27.4M
$31.1M
Free Cash Flow
PTGX
PTGX
RPD
RPD
Q4 25
$36.4M
Q3 25
$34.8M
Q2 25
$46.6M
Q1 25
$28.4M
Q4 24
$182.8M
$62.6M
Q3 24
$42.6M
Q2 24
$32.6M
Q1 24
$-27.7M
$30.4M
FCF Margin
PTGX
PTGX
RPD
RPD
Q4 25
16.8%
Q3 25
16.0%
Q2 25
21.8%
Q1 25
13.5%
Q4 24
107.1%
28.9%
Q3 24
19.9%
Q2 24
15.7%
Q1 24
-10.9%
14.8%
Capex Intensity
PTGX
PTGX
RPD
RPD
Q4 25
0.5%
Q3 25
1.9%
Q2 25
0.4%
Q1 25
0.6%
Q4 24
0.8%
0.5%
Q3 24
0.6%
Q2 24
0.1%
Q1 24
0.1%
0.3%
Cash Conversion
PTGX
PTGX
RPD
RPD
Q4 25
12.01×
Q3 25
3.97×
Q2 25
5.70×
Q1 25
14.14×
Q4 24
1.40×
29.36×
Q3 24
2.85×
Q2 24
5.03×
Q1 24
-0.13×
22.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PTGX
PTGX

Segment breakdown not available.

RPD
RPD

Products$209.1M96%
Services$8.2M4%

Related Comparisons